BioCentury
ARTICLE | Company News

FDA accepts brexpiprazole NDA

September 25, 2014 2:25 AM UTC

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and H. Lundbeck A/S (CSE:LUN) said FDA accepted for review an NDA for brexpiprazole to treat schizophrenia and as an adjunct treatment for major depressive disorder (MDD). The PDUFA date is July 11, 2015. ...